2008 a Record Year for Gerresheimer

- **Strong focus on the markets of pharma & life science**
- **Annual General Meeting passes dividend of €0.40 per share**

Düsseldorf, April 29, 2009 – The Annual General Meeting of Gerresheimer AG today passed an unchanged dividend of €0.40 per share following the record year in 2008.

The Company finished the financial year 2008 with record results. Gerresheimer achieved sales of €1.06 billion (prior year €957.7m) and operating results (adjusted EBITDA) of €206.4m (prior year €181.6m).

At the Annual General Meeting in Düsseldorf the CEO Dr. Axel Herberg summarized the highlights of the financial year 2008: “We have achieved record levels in terms of sales and earnings. Gerresheimer is on a good course and will show itself to be very robust even in times of crisis.”

The shareholders approved the actions of the members of the Company’s Supervisory Board and Management Board for the financial year 2008 and, as in the prior year, passed a dividend payment of €0.40 per share.

With share capital representation of 59.44% the Annual General Meeting passed the following resolutions:

ITEM 2: Appropriation of net earnings for the financial year 2008: (99.99% of votes in favor)

ITEM 3: Approval of the actions of the Management Board members for the financial year 2008: (100% of votes in favor)

ITEM 4: Approval of the actions of the Supervisory Board members for the financial year 2008: (100% of votes in favor)
ITEM 5: Supplementary election to the Supervisory Board of
Mr. Theodor Stuth, Auditor and Certified Tax Advisor, Neuss:
(100% of votes in favor)

ITEM 6: Election of the auditor for the financial year 2009:
(99.99% of votes in favor)


About Gerresheimer

Gerresheimer employs around 10,000 people in 42 locations in
Europe, America and Asia. In the financial year 2008, worldwide
sales totalled €1.06bn. The product portfolio ranges from pharma-
ceutical vials made of glass and plastic through to complex drug-
delivery systems for the pharma & life science industry. These include
sterile syringes, inhalers and other system-based approaches for safe
dosage and application of medications. The Group enjoys a leading
position in markets which are characterised by high technical and
regulatory barriers.

Contact Press
Burkhard Lingenberg
Director Corporate Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
e-mail b.lingenberg@gerresheimer.com

Contact Investor Relations
Anke Linnartz
Director Corporate Investor Relations
Phone +49 211 6181-314
Fax +49 211 6181-121
e-mail a.linnartz@gerresheimer.com